1-(3-Methoxypheny)indole-2-carboxylic acid | 128305-49-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(3-Methoxypheny)indole-2-carboxylic acid
• 英文别名: 1-(3-methoxyphenyl)indole-2-carboxylic acid
• CAS: 128305-49-7
• 化学式: C₁₆H₁₃NO₃
• 分子量: 267.284
• InChiKey: JGJGATZSBDRWIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  51.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-异丙基-4-哌啶胺 、 1-(3-Methoxypheny)indole-2-carboxylic acid 以 二氯甲烷 为溶剂， 生成 1-(3-Methoxy-phenyl)-1H-indole-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide
  参考文献：
  名称：

  Factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of neutral P1 substituents

  摘要：

  A series of novel, highly potent 2-carboxyindole-based factor Xa inhibitors is described. Structural requirements for neutral ligands, which bind in the S1 pocket of factor Xa were investigated with the 2-carboxyindole scaffold. This privileged fragment assembly approach yielded a set of equipotent, selective inhibitors with structurally diverse neutral P1 substituents. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.06.020
• 作为产物：
  描述：

  吲哚-2-羧酸乙酯 在 吡啶 、 lithium hydroxide 、 copper diacetate 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 122.0h， 生成 1-(3-Methoxypheny)indole-2-carboxylic acid
  参考文献：
  名称：

  Factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of neutral P1 substituents

  摘要：

  A series of novel, highly potent 2-carboxyindole-based factor Xa inhibitors is described. Structural requirements for neutral ligands, which bind in the S1 pocket of factor Xa were investigated with the 2-carboxyindole scaffold. This privileged fragment assembly approach yielded a set of equipotent, selective inhibitors with structurally diverse neutral P1 substituents. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.06.020

文献信息

• New indole derivatives as factor Xa inhibitors
  申请人：——

  公开号：US20030199689A1

  公开（公告）日：2003-10-23

  The present invention relates to compounds of formula I, 1 in which R 0 ; R 1 ; R 2 ; R 3 ; R 4 ; R 5 ; R 6 ; R 7 ; Q; V, G and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is indicated. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as pharmaceuticals for treating the foregoing conditions, and pharmaceutical preparations comprising them.

  本发明涉及具有式I的化合物，其中R0；R1；R2；R3；R4；R5；R6；R7；Q；V，G和M具有索赔中指示的含义。式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，例如，适用于治疗和预防心血管疾病如血栓栓塞疾病或再狭窄。它们是血凝酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，通常可应用于存在因子Xa和/或因子VIIa不良活性的情况，或者在其治疗或预防需要抑制因子Xa和/或因子VIIa的情况下。此外，本发明还涉及制备式I化合物的方法，它们的用途，特别是作为用于治疗上述疾病的药物，以及包含它们的制剂。
• 2,3-dihydro-2-(4,5-dihydroimidazol-2-yl)-indoles for reducing
  申请人：Ciba-Geigy Corporation

  公开号：US04912125A1

  公开（公告）日：1990-03-27

  Compounds of the formula ##STR1## wherein each R is hydrogen or one R is hydrogen and the other is lower alkyl, R.sub.1 is hydrogen, lower alkyl, aryl, aralkyl or lower carboalkoxy, R.sub.2 is hydrogen or lower alkyl, and the ring A is unsubstituted or substituted by lower alkyl, lower alkoxy, halo or trifluoromethyl, and pharmaceutically acceptable salts thereof, their preparation, pharmaceutical compositions and the uses thereof, such as .alpha..sub.2 -adrenergic blocking agents, e.g. antidepressants, cognition enhancers and appetite supressants, and as intraocular pressure reducing agents are disclosed.

  本发明公开了化学式为##STR1##的化合物，其中每个R是氢或一个R是氢，另一个是较低的烷基，R.sub.1是氢，较低的烷基，芳基，芳基烷基或较低的羧基烷氧基，R.sub.2是氢或较低的烷基，环A未经取代或被较低的烷基，较低的烷氧基，卤素或三氟甲基取代，以及其药学上可接受的盐，其制备，制药组合物和用途，例如作为α2-肾上腺素能阻断剂，例如抗抑郁剂，认知增强剂和食欲抑制剂，以及作为降低眼内压的剂。
• 2,3-dihydro-2-(4,5-dihydroimidazol-2-yl)-indoles in composition form for
  申请人：Ciba-Geigy Corporation

  公开号：US04908376A1

  公开（公告）日：1990-03-13

  Compounds of the formula ##STR1## wherein each R is hydrogen or one R is hydrogen and the other is lower alkyl, R.sub.1 is hydrogen, lower alkyl, aryl, aralkyl or lower carboalkoxy, R.sub.2 is hydrogen or lower alkyl, and the ring A is unsubstituted or substituted by lower alkyl, lower alkoxy, halo or trifluoromethyl, and pharmaceutically acceptable salts thereof, their preparation, pharmaceutical compositions and the uses thereof, such as .alpha..sub.2 -adrenergic blocking agents, e.g. antidepressants, cognition enhancers and appetite suppressants, and as intraocular pressure reducing agents are disclosed.

  本发明揭示了分子式为##STR1##的化合物，其中每个R是氢或一个R是氢，另一个是低碳基，R.sub.1是氢、低碳基、芳香基、芳香烷基或低碳基羧酸酯，R.sub.2是氢或低碳基，环A是未取代或被低碳基、低氧基、卤素或三氟甲基取代，以及其药学上可接受的盐，它们的制备、制药组合物和用途，例如α.sub.2-肾上腺素能阻断剂，例如抗抑郁剂、认知增强剂和食欲抑制剂，以及作为降低眼压的药物。
• NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS
  申请人：NAZARE Mark

  公开号：US20090069565A1

  公开（公告）日：2009-03-12

  The present invention relates to compounds of formula I, in which R 0 ; R 1 ; R 2 ; R 3 ; R 4 ; R 5 ; R 6 ; R 7 ; Q; V, G and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is indicated. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as pharmaceuticals for treating the foregoing conditions, and pharmaceutical preparations comprising them.

  本发明涉及式I的化合物，其中R0; R1; R2; R3; R4; R5; R6; R7; Q; V，G和M具有声明中指示的含义。式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，例如适用于治疗和预防心血管疾病，如血栓栓塞性疾病或再狭窄。它们是血凝酶酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，并且通常可以应用于存在因子Xa和/或因子VIIa不良活性的情况，或者治疗或预防需要抑制因子Xa和/或因子VIIa的情况。此外，本发明还涉及制备式I化合物的方法，它们的用途，特别是作为治疗上述疾病的药物以及包含它们的制药制剂。
• Acidic indole compounds and their use as antiallergy agents
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0186367A2

  公开（公告）日：1986-07-02

  There are disclosed compounds having the following general formula (I): and pharmaceutically acceptable salts thereof, wherein: R' and Q are each, independently, H, an alkyl having from one to twelve carbon atoms, an alkoxy having from one to twelve carbon atoms, mercapto. an alkylthio having from one to four carbon atoms, an alkylsulphinyl having from one to four carbon atoms, an alkylsulphonyl having from one to four carbon atoms, a hydroxy group, a nitro group, an amino group, substituted amino group or a halogen, R' being further chosen from a methylenedioxy radical attached to adjacent carbon atoms of the benzene ring; R2 is H, an alkyl having from one to twelve carbon atoms, a phenyl radical, a substituted phenyl radical or a benzyl radical; R3 is H, an alkyl having from one to twelve carbon atoms, an alkoxy having from one to twelve carbon atoms, mercapto, an alkylthio having from one to four carbon atoms, a phenylthio radical, a substituted phenylthio radical, an alkylsulphinyl having from one to four carbon atoms, a phenylsulphinyl radical, a substituted phenylsulphinyl radical, an alkylsulphonyl hving from one to four carbon atoms, a phenylsolphonyl radical, a substituted phenylsolphonyl radical an amino group, or a substitued amino group; and R4 is Methods of preparing the compounds, compositions comprising the compounds and the pharmaceutical use of the compounds are also disclosed.

  公开了具有以下通式(I)的化合物： 及其药学上可接受的盐类，其中 R'和 Q 各自独立地为 H、1-12 个碳原子的烷基、1-12 个碳原子的烷氧基、1-4 个碳原子的巯基、1-4 个碳原子的烷硫基、1-4 个碳原子的烷基亚磺酰基、1-4 个碳原子的烷基磺酰基、羟基、硝基、氨基、取代氨基或卤素，R'可进一步选自连接到苯环相邻碳原子上的亚甲二氧基； R2 是 H、具有 1 至 12 个碳原子的烷基、苯基、取代苯基或苄基； R3 是 H、具有一至十二个碳原子的烷基、具有一至十二个碳原子的烷氧基、巯基、具有一至四个碳原子的烷硫基、苯硫基、取代的苯硫基、具有一至四个碳原子的烷基亚磺酰基、一个氨基或一个取代氨基；和 R4 是 还公开了制备这些化合物的方法、包含这些化合物的组合物以及这些化合物的药物用途。